In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results